Roivant Sciences Cash Flow Statement

Financials in millions USD. Fiscal year is April - March.

Millions USD. Fiscal year is Apr - Mar.

Year Ending	TTM	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022	Mar 31, 2021	Mar 31, 2020
Net Income	4,349	4,349	-1,009.03	-845.26	-809.23	1,201
Depreciation & Amortization	28.88	28.88	26.42	13.2	0	0
Share-Based Compensation	199.63	199.63	217.78	564.96	84.96	122.57
Other Operating Activities	-5,342.7	-5,342.7	-78.57	-410.63	172.14	-2,081.83
Operating Cash Flow	-765.27	-765.27	-843.39	-677.73	-552.14	-758.75
Capital Expenditures	-1.38	-1.38	-12.69	-17.44	-5.81	-4.92
Acquisitions	5,196	5,196	-32.28	-0.04	0	1,715
Change in Investments	0	0	0	320.17	0	-15.64
Other Investing Activities	8.59	8.59	0.7	0.6	-25.9	-
Investing Cash Flow	5,204	5,204	-44.27	303.3	-31.7	1,695
Share Issuance / Repurchase	200.74	200.74	312.3	213.42	0	115.11
Debt Issued / Paid	-30.71	-30.71	129.76	14.81	0	153.29
Other Financing Activities	249.33	249.33	57.41	78.56	456.26	-54.31
Financing Cash Flow	419.36	419.36	499.46	306.79	456.26	214.08
Exchange Rate Effect	0.62	0.62	6.28	0	0	0
Net Cash Flow	4,858	4,858	-381.92	-67.64	-127.58	1,150
Free Cash Flow	-766.65	-766.65	-856.08	-695.17	-557.94	-763.67
Free Cash Flow Margin	-614.33%	-614.33%	-1397.00%	-1257.40%	-2344.80%	-1128.20%
Free Cash Flow Per Share	-0.98	-0.98	-1.20	-1.04	-0.89	-3.49

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).